- Home
- BTAI
as 05-17-2024 4:00pm EST
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 77.7M | IPO Year: | 2018 |
| Target Price: | $6.00 | AVG Volume (30 days): | 642.6K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.91 - $27.20 | Next Earning Date: | 05-09-2024 |
| Revenue: | $1,756,000 | Revenue Growth: | 202.24% |
| Revenue Growth (this year): | 163.62% | Revenue Growth (next year): | 286.42% |
Share on Social Networks:
Stock Insider Trading Activity of BioXcel Therapeutics Inc. (BTAI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wiley Matthew T. | BTAI | CHIEF COMMERCIAL OFFICER | Mar 15 '24 | Sell | $2.64 | 1,008 | $2,656.18 | 2,992 | SEC Form 4 |
| Steinhart Richard I | BTAI | Chief Financial Officer | Mar 14 '24 | Sell | $2.64 | 1,069 | $2,816.81 | 4,765 | SEC Form 4 |
| O'Neill Vincent | BTAI | See Remarks | Mar 14 '24 | Sell | $2.62 | 165 | $432.48 | 5,408 | SEC Form 4 |
| Mehta Vimal | BTAI | CEO and President | Mar 14 '24 | Sell | $2.62 | 829 | $2,171.98 | 48,003 | SEC Form 4 |
| Mehta Vimal | BTAI | CEO and President | Mar 14 '24 | Sell | $2.62 | 4,439 | $11,651.04 | 43,564 | SEC Form 4 |
| Rodriguez Javier | BTAI | See Remarks | Mar 14 '24 | Sell | $2.64 | 1,012 | $2,667.43 | 7,672 | SEC Form 4 |
| Yocca Frank | BTAI | Chief Scientific Officer | Mar 14 '24 | Sell | $2.64 | 1,067 | $2,811.54 | 12,763 | SEC Form 4 |
Latest BioXcel Therapeutics Inc. News
BTAI Breaking Stock News: Dive into BTAI Ticker-Specific Updates for Smart Investing
Insider Monkey
9 days ago
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript
Simply Wall St.
10 days ago
BioXcel Therapeutics First Quarter 2024 Earnings: Misses Expectations
Thomson Reuters StreetEvents
10 days ago
Q1 2024 BioXcel Therapeutics Inc Earnings Call
GlobeNewswire
11 days ago
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
GlobeNewswire
25 days ago
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
GlobeNewswire
25 days ago
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
GlobeNewswire
a month ago
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
GlobeNewswire
a month ago